Nijmegen, the Netherlands – (August 20, 2024) – Thirona, a global company specialized in advanced analysis of  medical lung images with artificial intelligence (AI), today announces the divestment of Thirona Retina BV ("Thirona Retina") to Revenio Group Corporation’s subsidiary Icare Finland Oy. Demonstrating impressive growth and tremendous market potential, the Retina division of Thirona was spun off into Thirona Retina in 2023 to focus entirely on the eye disease market.

By joining forces with iCare, a market leader in eye care solutions, Thirona Retina is poised to enhance patient outcomes and drive innovation in eye care. Leveraging iCare’s market presence and expertise, Thirona Retina will now bring its cutting-edge AI-driven RetCAD™ technology—designed to screen fundus images for diabetic retinopathy, age-related macular degeneration, and glaucoma—to a wider global audience, revolutionizing eye care. Integrated into iCare’s ILLUME and other retinal screening solutions, RetCAD™ has been consistently validated by independent clinical studies and has received strong customer reception across Europe and Asia-Pacific.

“After years of research and development, we’ve created a reliable, clinically validated product with a strong market presence. Combining our expertise with iCare’s resources will accelerate the adoption of RetCAD™ and broaden its impact, transforming eye care on a global scale,” said Mark van Grinsven, Managing Director of Thirona Retina. “As we continue supporting further development of the ILLUME solution, we will also maintain our commitment to offering RetCAD™ to other platforms and eye care providers. I’m looking forward to continuing this journey with the iCare team.”

“Icare and Thirona share the vision of developing AI-powered solutions that elevate patient outcomes. We’re proud of the rapid growth and market disruption achieved by our Retina division, and we look forward to seeing RetCAD™ grow further,” said Eva van Rikxoort, CEO & Founder of Thirona. “This divestment allows Thirona to sharpen its focus on its long-term growth strategy in AI-driven lung imaging for pulmonary precision medicine and fuel new growth in the interventional pulmonology space.”

Since receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for its AI-based clinical software, LungQ™ (v3.0.0), earlier this year, Thirona has solidified several partnerships to enhance integration of the software into clinical settings. Furthermore, Thirona recently announced the addition of top clinical experts in interventional pulmonology and bronchoscopy to its Medical Advisory Board, further supporting its mission to develop personalized approaches to lung disease treatment.

Media contact: mediarelations@thirona.eu